JPRN-jRCT2080220186未知3 期
ToGA study: A Study of R597 (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer.
适应症
试验速览
- 阶段
- 3 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •-Male or Female patients (>=18 years of age);
- •-Inoperable locally advanced, recurrent, or metastatic cancer of the stomach or gastroesophageal junction;
- •-Adenocarcinoma;
- •-HER2-positive tumors.
- •Exclusion criteria:
- •-Previous chemotherapy for adavanced/metastatic disease;
- •-Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome;
- •-History of cardiac deisease;
- •-Dyspnoea at rest, due to complications of advanced malignancy or other disease, or patients who require supportive oxygen therapy.
排除标准
- 未提供
研究者
相似试验
尚未招募
不适用
plus cisplatin for HER2-positive biliary tract cancerKCT0003158Asan Medical Center15
招募中
不适用
A phase II clinical study of trastuzumab in combination with capecitabine and cisplatin (XP) in patients with tissue HER2-negative but serum HER2-positive advanced gastric cancerNeoplasmsKCT0004391Asan Medical Center28
招募中
2 期
Phase II single-arm study of Trastuzumab combination with Cisplatin and Gemcitabine as first-line therapy in the HER-2 positive Advanced CholangioCArcinomaAdvanced biliary tract cancersHER-2 positiveFirst-line therapyGallbladder CancerBiliary Tract CancersOncogene Protein HER-2TrastuzumabCisplatinGemcitabineCancer Chemotherapy AgentCombined Antineoplastic AgentsCholangiocarcinomaTCTR20220328005Khon Kaen University33
进行中（未招募）
不适用
Study of Trastuzumab in Combination with Lapatinib or Pertuzumab in Combination with Trastuzumab in HER2-positive Metastatic Colorectal CancerEUCTR2012-002128-33-ITFONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO
已完成
2 期
The effect of anti-HER2 therapy in metastatic breast cancer wih HER2-negative primary tumor but HER2-positive circulating tumor cells<p>Breast cancer, borstkanker, HER2, ER, PIK3CA, CTC, circulating tumor cell, circulerende tumorcellen, metastasen, metastasis, trastuzumab, herceptin, docetaxel</p>10006232NL-OMON20549Erasmus MC Cancer Institute, department of Medical Oncology18